1672 results about "Staphylococcus aureus bacteria" patented technology

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

The invention discloses staphylococcus NHY-25 capable of producing enzyme and aroma, which is preserved in Guangdong Microbial Culture Collection Center on May 26, 2025, and the preservation number is GDMMC NO: 66396. When the strain is applied to yeast strengthening, the enzyme activity in high-temperature yeast can be improved, for example, the activity of protease, saccharifying power, fermenting power and liquefying power of yeast can be improved. Through detection of volatile compounds in the strengthened Daqu and the unstrengthened Daqu, it is found that the strain enables the variety and content of the volatile compounds in the strengthened Daqu to be improved. The strain enables the sauce flavor of high-temperature yeast to be more prominent, can be applied to yeast strengthening, and provides a new thought for improving the quality of yeast.

The invention discloses an antibacterial peptide based on D-type amino acid and application of the antibacterial peptide, and the antibacterial peptide is characterized in that the amino acid sequence is w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized through an Fmoc solid-phase chemical method, the synthesis difficulty is low, and the in-vivo antibacterial activity is good. The antibacterial peptide especially has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, is low in hemolytic toxicity, can reach half or more of cell survival rate under medium and low concentration, almost has no toxic effect on cells, and can be used for preparing the antibacterial peptide with a broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus. The stability is good, the operability is high, and the cost is low.

The invention relates to Penicillium decumbens C01 and application of the Penicillium decumbens C01, and belongs to the technical field of microorganisms. The penicillium decumbens C01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the penicillium decumbens C01 is GDMCC NO.66456. The strain is obtained by separating, purifying and screening soil samples collected from botanical gardens in South China of Guangzhou; tests show that the bacteriostatic active substance generated by fermentation of the strain has a good bacteriostatic effect on staphylococcus epidermidis, staphylococcus aureus, escherichia coli, propionibacterium acnes, candida albicans and pseudomonas aeruginosa, and the bacteriostatic active substance has the characteristic of high temperature resistance and excellent preservative effect; the antibacterial preservative can be used as an antibacterial preservative raw material, is applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The invention belongs to the technical field of antibiosis and wound healing promotion, and relates to double-response (near-infrared light and hydrogen peroxide double-response photo-thermal / carbon monoxide therapy) antibacterial hydrogel as well as preparation and application thereof. The invention relates to a double-response antibacterial hydrogel. The antibacterial hydrogel is prepared from the following components: drug-loaded nano particles and a hydrogel matrix. The drug-loaded nano particles are prepared by loading dimanganese decacarbonyl (MnCO) into cavities of hollow mesoporous copper sulphide nano particles (HMCuS NPs) and coating the surfaces of the particles with a polydopamine layer (PDA). According to the invention, CO / PTT synergistic treatment of bacterial infected wounds is realized, and the antibacterial effect is significantly improved. An in-vitro antibacterial experiment result shows that the antibacterial hydrogel shows extremely strong inhibition capability on escherichia coli and staphylococcus aureus, and the problem of drug resistance caused by a bacterial biofilm is effectively solved.

The invention discloses preparation and application of an anti-staphylococcus aureus IsdB antibody. The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 8; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 16. The invention also provides nucleic acid for coding the antibody, a vector containing the nucleic acid and a cell containing the vector. In addition, experiments prove that the antibody can inhibit systemic infection of MRSA and resist invasion of MRSA to pneumonia, and has a good clinical application prospect.

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses an antibacterial peptide fragment intercepted from chitinase IDGF4 protein and application of the antibacterial peptide fragment in preparation of antibacterial drugs. According to the invention, short peptide fragments in chitinase IDGF4 protein are screened, three candidate peptides are obtained through chemical synthesis, the antibacterial performance of the candidate peptides is systematically evaluated, and the evaluation result shows that the peptide fragment with the amino acid sequence as shown in SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg / mL; the antibacterial effect of the compound is confirmed in inhibition zone experiments, enzyme-labeled turbidimetry and growth curve monitoring, and the compound shows stable and remarkable antibacterial activity and can be used as a novel antibacterial molecule; the invention provides a new candidate sequence for developing the antibacterial peptide with high efficiency and low drug resistance risk, and has application potential in the aspect of preparing clinical antibacterial drugs.

The invention provides a kit for rapidly detecting MRSA and drug-resistant gene nucleic acid POCT of the MRSA based on a phage lyase mutant. The kit comprises nucleic acid extraction and purification and triple PCR rapid amplification detection reagents. The staphylococcus aureus bacteriophage lyase mutant nucleic acid release liquid containing the amino acid sequence as shown in SEQ ID NO: 1 is adopted, wall breaking can be rapidly conducted on staphylococcus aureus, and nucleic acid is released. The effect of the nucleic acid release liquid acting for 5 minutes is equivalent to or even better than that of the lysozyme acting for 60 minutes; according to the present invention, with the combination of the MRSA and drug-resistant gene triple PCR rapid amplification detection reagent, the total detection time is only 35 min, the time is saved by 55 min or more than 55 min compared with the lysozyme method, and the MRSA and drug-resistant gene nucleic acid POCT rapid detection can be achieved;

The invention discloses a staphylococcus aureus biosensor based on a nucleic acid aptamer and a preparation method of the staphylococcus aureus biosensor. Three fluorine atoms (F) are introduced into the 5'end, the 3 'end and the middle position of an aptamer 2' F3-(5 '3'm DNA) sequence (SEQ ID NO: 1) for modification, so that the binding force of the aptamer and graphene is remarkably enhanced, the signal stability and the anti-interference capability of the biosensor are remarkably improved, non-specific fluorescence leakage can be effectively blocked, and reliable guarantee is provided for complex sample detection. According to the present invention, with the cooperation of the graphene oxide quenching substrate, the high-sensitivity detection of the staphylococcus aureus is achieved, the detection limit of the sensor within 5 min can achieve 5 cells / mL, the sensitivity is high, the specificity on the complex sample is more than 95.4%, and the sensor is suitable for the food safety rapid screening and the clinical diagnosis.

This invention relates to the technical field of deep processing of sturgeon by-products, and particularly to a sturgeon tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method. The preparation method includes the following steps: mixing sturgeon with water and crushing it to form a first slurry; adding Bacillus licheniformis alkaline protease to the first slurry for a first hydrolysis; adding Bacillus subtilis neutral protease to the first hydrolysate for a second hydrolysis; adding a complex enzyme to the second hydrolysate for a third hydrolysis to obtain a sturgeon tendon hydrolysate; filtering the sturgeon tendon hydrolysate to remove impurities to obtain a filtrate, which is then filtered again to retain polypeptides, thus obtaining the sturgeon tendon peptide; wherein the complex enzyme includes pectinase and amylase. Using this method, a sturgeon tendon peptide with high glycosaminoglycan content can be obtained, which exhibits pancreatic lipase inhibitory activity, antioxidant activity, Staphylococcus aureus inhibitory activity, and prebiotic effects that promote the proliferation of Lactobacillus plantarum and Lactobacillus fermentum.

The invention relates to epsilon-polylysine epsilon-PL-loaded modified rice bran protein antibacterial nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of preparation of nanoparticles. The preparation method comprises the following steps: extracting rice bran protein from defatted rice bran to prepare a rice bran protein stock solution; under continuous stirring, adding succinic anhydride into the rice bran protein stock solution to obtain acylated rice bran protein; mixing the acylated rice bran protein stock solution, the lactose stock solution and the epsilon-PL stock solution; and centrifuging and freeze-drying to obtain the epsilon-PL-loaded modified rice bran protein antibacterial nanoparticles. The preparation method disclosed by the invention is simple and low in cost, the prepared nanoparticles have smaller particle size and turbidity and higher stability, the hygroscopicity of epsilon-PL can be reduced to a great extent, the bioavailability of epsilon-PL can be improved, and the nanoparticles have an obvious bacteriostatic effect on escherichia coli and staphylococcus aureus.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention belongs to the field of polypeptides, and particularly relates to an antibacterial peptide derived from marine microorganisms, an antibacterial composition and application. Based on a deep learning algorithm, five potential antibacterial peptides are mined from a global marine microbiome database, and the five antibacterial peptides are expressed in yarrowia lipolytica. Experimental tests show that the five antibacterial peptides have differentiated antibacterial effects on different bacteria, and the antibacterial peptide shown in SEQ ID NO: 3 can have an obvious inhibition effect on escherichia coli, pseudomonas aeruginosa and staphylococcus aureus, has low hemolysis and has a positive application prospect. The antibacterial peptide disclosed by the invention has the potential of further developing novel antibacterial drugs or antibacterial additives.

The invention discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide has an amino acid sequence as shown in any one of SEQ ID NO: 1-11. The antibacterial peptide prepared by the scheme provided by the invention has very strong bacteriostasis and sterilization capabilities on methicillin-resistant staphylococcus aureus and multidrug-resistant escherichia coli, has application potential of becoming an antibacterial agent, a preservative or a disinfectant, and is not easy to generate drug resistance.

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The invention provides a recombinant chicken antibacterial peptide aiming at drug-resistant staphylococcus aureus, and belongs to the technical field of veterinarians. The recombinant chicken antibacterial peptide is expressed through genetic engineering recombinant escherichia coli. Three natural chicken antibacterial peptide active regions are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to staphylococcus aureus outer membrane protein. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to the drug-resistant staphylococcus aureus is obviously lower than that of three natural chicken antibacterial peptides, and the formation of a biomembrane of a USA300 strain of the drug-resistant staphylococcus aureus can be thoroughly inhibited when the minimum inhibitory concentration is 8 mu g / mL. The recombinant chicken antibacterial peptide has a good antibacterial effect on different drug-resistant staphylococcus aureus separated from a chicken house, and can effectively solve the infection problem of the drug-resistant staphylococcus aureus in the chicken house.

The invention relates to the technical field of microorganisms, in particular to space breeding combined lactobacillus salivarius ZK-88-S and application thereof. The combined lactobacillus salivarius ZK-88-S disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2024, and the preservation number is CGMCC No.33181; the combined lactobacillus salivarius ZK-88-S can inhibit escherichia coli, staphylococcus aureus, candida albicans, pseudomonas aeruginosa, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus salivarius, streptococcus gordoni or actinomyces naessii, and can be applied to preparation of medicines, daily necessities or health-care foods for oral treatment and oral cleaning.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention discloses self-cleaning antibacterial domestic ceramic and glaze and a preparation process thereof. The preparation process comprises the following steps: step 1, early-stage research and innovative conception; 2, determining a core raw material and a formula; step 3, pretreating the raw materials; step 4, glaze preparation process; step 5, preparing a domestic ceramic green body; step 6, glazing and sintering process; the preparation method has the advantages that nano titanium dioxide added in the glaze can generate free radicals with strong oxidizing property under illumination, organic pollutants on the surface of ceramic can be decomposed, the self-cleaning function is achieved, meanwhile, nano silver and silver-loaded zirconium phosphate have good antibacterial performance, breeding of various bacteria can be effectively inhibited, the anti-bacterial performance is good, the service life of the glaze is prolonged, and the service life of the glaze is prolonged. The antibacterial rate on common bacteria such as escherichia coli and staphylococcus aureus can reach 95% or above, the raw materials are wide in source and meet the environment-friendly requirement, the conventional ball milling, forming, glazing and firing processes are adopted, industrial production is easy, the cost is low, and large-scale popularization of the product is facilitated.

The invention discloses marine-derived penicillium as well as a fermentation method and application thereof. The marine source penicillium is named as Penicillium sp.DSF059, and the preservation number of the marine source penicillium is CCTCC (China Center For Type Culture Collection) NO: M 20232310. According to the invention, the culture conditions of the strain are optimized, the culture medium and culture conditions with high yield of antibacterial active compounds are selected for fermentation, more target products can be obtained, the operation is simple, the cost is low, and the method is suitable for industrial production. Meanwhile, the marine-derived penicillium sp. DSF059 can provide an excellent strain for the development of new drugs for resisting plant pathogens such as coffee leaf blight, coffee brown spot, grape gray mold, golden cypress brown spot, citrus black rot, phytophthora capsici, hickory leaf blight and coffee black spot as well as four pathogens separated from coffee leaf diseases and staphylococcus aureus; good application prospects are realized on prevention and treatment of phytopathogen and staphylococcus aureus.

The invention discloses an antibacterial sanitary towel packaging bag and a preparation method thereof. The antibacterial sanitary towel packaging bag comprises a base material layer, an antibacterial layer and a leakage-proof layer. The base material layer is prepared by blending modified polylactic acid, polybutylene adipate and the like and contains a degradation accelerant; the antibacterial layer contains antibacterial peptide-loaded nano montmorillonite, chitosan and the like, and loofah sponge fiber enhances slow release; and the leakage-proof layer is an ethylene-vinyl acetate copolymer and modified silicon dioxide blended film and is provided with breathable micropores. The preparation method comprises the steps of forming the base material layer, coating the antibacterial layer and the like, and process parameters of each layer are accurately controlled. According to the packaging bag, through cooperation of three layers, the bacteriostasis rate of the packaging bag on escherichia coli and staphylococcus aureus in 24 hours is higher than 99%, the degradation rate of the packaging bag in 83 days is higher than 88%, the oxygen permeability is 4.5-5.2 cm < 3 > / (m224h 0.1 MPa), and the packaging bag has the advantages of long-acting antibiosis, air permeability, leakage prevention, environmental protection, degradation and good mechanical properties, and meets the storage and use requirements of sanitary napkins.

The invention belongs to the field of plant endophytic fungus secondary metabolites, particularly relates to a secondary metabolite of fennel endophytic fungus fusarium oxysporum as well as a preparation method and application thereof, and provides a fennel endophytic fungus secondary metabolite with structures as shown in compounds 1-8. Wherein the compound 2 and the compound 7 have inhibitory activity on staphylococcus aureus, escherichia coli, bacillus cereus, bacillus subtilis, candida albicans and shigella, and have a certain inhibitory effect on cervical cancer Hela cell strains.

This invention discloses a primer and probe set, a kit, and their applications for detecting Staphylococcus aureus L based on real-time fluorescence MIRA technology. The primer and probe set consists of single-stranded DNA sequences 1-3. Based on the aforementioned primer and probe set, this invention establishes and optimizes a real-time fluorescence MIRA detection method for Staphylococcus aureus L. Furthermore, the optimized real-time fluorescence MIRA method is innovatively combined with a simplified nucleic acid extraction method and a portable fluorescence detection device, significantly reducing extraction and time costs while enabling rapid on-site detection of the virus, making it particularly suitable for grassroots units and remote areas. In addition, the real-time fluorescence MIRA detection method for Staphylococcus aureus L established in this invention has advantages such as high specificity, high sensitivity, and simple operation. Moreover, the detection process does not require opening the lid, effectively avoiding aerosol contamination, providing an effective technical means for the differential diagnosis and rapid detection of Staphylococcus aureus L.

The invention relates to a Paenibacillus polymyxa strain B01 and application of the Paenibacillus polymyxa strain B01, and belongs to the technical field of microorganisms. The paenibacillus polymyxa B01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the paenibacillus polymyxa B01 is GDMCC NO.66594. The strain is obtained by separation, purification and screening from a soil sample, and tests show that the strain has excellent pH and high temperature tolerance; antibacterial active substances generated by fermentation of the bacillus subtilis have a relatively good antibacterial effect on escherichia coli, pseudomonas aeruginosa, pseudomonas putida, staphylococcus aureus, candida albicans, aspergillus brazilis, propionibacterium acnes and malassezia; and the antibacterial active substance has excellent heat resistance, cold resistance, illumination stability, pH stability and preservative effect, belongs to a mild low-irritation raw material, can be used for preparing daily chemical products and medicines, and has wide application prospects and important conversion research values.

Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus. The method comprises the steps of applying a photosensitizer to at least a part of the skin affected by the infection, and subjecting said part of the skin to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level; and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 10:1 to 2:1. By the method efficient treatment of Staphylococcus aureus infections can be achieved without the administration of topical antibiotics.

The invention relates to the technical field of textile fabrics, in particular to an antibacterial composite fabric and a preparation process thereof. Comprising the following steps: S1, treating a fabric for 30 minutes at 100 DEG C by using a NaOH aqueous solution according to a bath ratio of 1: 50, washing the fabric with deionized water, and drying the fabric at 80 DEG C; soaking the fabric in the finishing agent according to a bath ratio of 1: 40, soaking at 40 DEG C for 24 hours, washing with deionized water, and drying at 80 DEG C; s2, 50 g of the fabric obtained in the step S1 is soaked in 150 mL of a curcumin-coated UiO-66-NH2 compound aqueous solution, and soaking is conducted for 24 h at the temperature of 30 DEG C; and then drying to obtain the antibacterial composite fabric. Through low-temperature finishing of natural curcumin-UiO-66-NH2-MOF, the cotton fabric can obtain the antibacterial rate of more than or equal to 96% of escherichia coli and more than or equal to 98% of staphylococcus aureus within the active component range of 20-80 g / L, and the antibacterial retention rate is still more than or equal to 80% after 50 times of industrial washing; the process is mild and does not damage cotton fibers.